ETF Managers Group’s Aligos Therapeutics ALGS Stock Holding History

ETF Managers Group’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-540	Closed	-$17K	–	704
2022 Q2	$17K	Buy	540 +23	+4%	+$781	﹤0.01%	741
2022 Q1	$27K	Buy	517 +2	+0.4%	+$160	﹤0.01%	679
2021 Q4	$154K	Sell	515 -107	-17%	-$39K	﹤0.01%	621
2021 Q3	$236K	Buy	622 +172	+38%	+$68K	﹤0.01%	608
2021 Q2	$238K	Sell	450 -17	-4%	-$10.8K	﹤0.01%	602
2021 Q1	$244K	Sell	467 -275	-37%	-$183K	﹤0.01%	603
2020 Q4	$482K	Buy	+742	New	+$361K	0.01%	362

Other funds holding ALGS

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ETF Managers Group's ALGS Position: Q3 2022 in Review

ETF Managers Group sold out of Aligos Therapeutics (ALGS) in Q3 2022, closing a stake of 540 shares — an estimated $17K sold.

ETF Managers Group first reported a position in ALGS in Q4 2020 and held it in 7 quarters. The position peaked at $482K in Q4 2020. 52 funds tracked by Wall St. Rank hold ALGS as of Q3 2022.

ETF Managers Group reported no remaining Aligos Therapeutics position as of Q3 2022 after selling out during the quarter.
ETF Managers Group sold 540 Aligos Therapeutics shares in Q3 2022, an estimated $17K.
ETF Managers Group first reported a position in Aligos Therapeutics in Q4 2020 and held it in 7 quarters.
ETF Managers Group's Aligos Therapeutics position peaked at $482K in Q4 2020.
52 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2022.

Based on ETF Managers Group's 13F filing for Q3 2022, filed 14 Nov 2022.